Key factors driving the growth of the inhaled antibiotics market include rising incidence of chronic respiratory disorders, worldwide. Some of the most common are chronic obstructive pulmonary disease (COPD), occupational lung diseases, asthma, and pulmonary hypertension. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), around 65 million people suffer from COPD and around 3 million die from it each year, making it the third leading cause of death worldwide. Thus, with increasing prevalence of aforementioned chronic respiratory diseases, the demand for inhaled antibiotics is also increasing rapidly.
Inhaled antibiotics are used for the treatment of chronic airway infection. Inhaled antibiotics allow the antibiotics to reach deep into the lungs to treat the bacteria that cause infection. They are an attractive alternative for patients with pulmonary infections. The objective of inhaled antibiotics is to provide the highest concentrations of active drug at the site of infection without risking systemic toxicity. Moreover, there is an increasing demand for inhaled antibiotics in targeted drug delivery, driving growth of the inhaled antibiotics market. Apulmiq is a late-stage investigational inhaled antibiotic for the treatment of non-cystic fibrosis bronchiectasis (NCFB). Such initiatives by market players are also expected to accelerate the growth of the inhaled antibiotics market. Read More : https://bit.ly/3s9a5NR
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2021
Categories |